Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose

Relay Therapeutics, Inc.

Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.
Patients at lower doses (n=14): 36% ORR; median DoR 5.6 months.
Safety consistent with prior data: no Grade 4/5 AEs; off-target hyperphosphatemia/diarrhea clinically insignificant.
Data cut-off Jan 30, 2023; presentation at ASCO on June 4, 2023.
Pivotal cohort enrollment completion and initial non-CCA expansion data expected in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.